Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and affects about 8% of cirrhotic patients, with a recurrence rate of over 50%. There are numerous therapies available for the treatment of HCC, depending on cancer staging and condition of the patient. The complexity of the trea...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Analytical Cellular Pathology |
| Online Access: | http://dx.doi.org/10.1155/2021/1840069 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564128253739008 |
|---|---|
| author | Argyrios Periferakis Georgios Tsigas Aristodemos-Theodoros Periferakis Ioana Anca Badarau Andreea-Elena Scheau Mircea Tampa Simona Roxana Georgescu Andreea Cristiana Didilescu Cristian Scheau Constantin Caruntu |
| author_facet | Argyrios Periferakis Georgios Tsigas Aristodemos-Theodoros Periferakis Ioana Anca Badarau Andreea-Elena Scheau Mircea Tampa Simona Roxana Georgescu Andreea Cristiana Didilescu Cristian Scheau Constantin Caruntu |
| author_sort | Argyrios Periferakis |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is the most common primary liver cancer and affects about 8% of cirrhotic patients, with a recurrence rate of over 50%. There are numerous therapies available for the treatment of HCC, depending on cancer staging and condition of the patient. The complexity of the treatment is also justified by the unique pathogenesis of HCC that involves intricate processes such as chronic inflammation, fibrosis, and multiple molecular carcinogenesis events. During the last three decades, multiple in vivo and in vitro experiments have used somatostatin and its analogs (SSAs) to reduce the proliferative and metastatic potential of hepatoma cells by inducing their apoptosis and reducing angiogenesis and the inflammatory component of HCC. Most experiments have proven successful, revealing several different pathways and mechanisms corresponding to the aforementioned functions. Moreover, a correlation between specific effects and expression of somatostatin receptors (SSTRs) was observed in the studied cells. Clinical trials have tested either somatostatin or an analog, alone or in combination with other drugs, to explore the potential effects on HCC patients, in various stages of the disease. While the majority of these clinical trials exhibited minor to moderate success, some other studies were inconclusive or even reported negative outcomes. A complete evaluation of the efficacy of somatostatin and SSAs is still the matter of intense debate, and, if deemed useful, these substances may play a beneficial role in the management of HCC patients. |
| format | Article |
| id | doaj-art-799d5a0bbe22429189985fba0bec83ae |
| institution | Kabale University |
| issn | 2210-7185 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Analytical Cellular Pathology |
| spelling | doaj-art-799d5a0bbe22429189985fba0bec83ae2025-02-03T01:11:40ZengWileyAnalytical Cellular Pathology2210-71852021-01-01202110.1155/2021/1840069Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular CarcinomaArgyrios Periferakis0Georgios Tsigas1Aristodemos-Theodoros Periferakis2Ioana Anca Badarau3Andreea-Elena Scheau4Mircea Tampa5Simona Roxana Georgescu6Andreea Cristiana Didilescu7Cristian Scheau8Constantin Caruntu9Department of PhysiologyDepartment of PhysiologyDepartment of PhysiologyDepartment of PhysiologyDepartment of Radiology and Medical ImagingDepartment of DermatologyDepartment of DermatologyDivision of EmbryologyDepartment of PhysiologyDepartment of PhysiologyHepatocellular carcinoma (HCC) is the most common primary liver cancer and affects about 8% of cirrhotic patients, with a recurrence rate of over 50%. There are numerous therapies available for the treatment of HCC, depending on cancer staging and condition of the patient. The complexity of the treatment is also justified by the unique pathogenesis of HCC that involves intricate processes such as chronic inflammation, fibrosis, and multiple molecular carcinogenesis events. During the last three decades, multiple in vivo and in vitro experiments have used somatostatin and its analogs (SSAs) to reduce the proliferative and metastatic potential of hepatoma cells by inducing their apoptosis and reducing angiogenesis and the inflammatory component of HCC. Most experiments have proven successful, revealing several different pathways and mechanisms corresponding to the aforementioned functions. Moreover, a correlation between specific effects and expression of somatostatin receptors (SSTRs) was observed in the studied cells. Clinical trials have tested either somatostatin or an analog, alone or in combination with other drugs, to explore the potential effects on HCC patients, in various stages of the disease. While the majority of these clinical trials exhibited minor to moderate success, some other studies were inconclusive or even reported negative outcomes. A complete evaluation of the efficacy of somatostatin and SSAs is still the matter of intense debate, and, if deemed useful, these substances may play a beneficial role in the management of HCC patients.http://dx.doi.org/10.1155/2021/1840069 |
| spellingShingle | Argyrios Periferakis Georgios Tsigas Aristodemos-Theodoros Periferakis Ioana Anca Badarau Andreea-Elena Scheau Mircea Tampa Simona Roxana Georgescu Andreea Cristiana Didilescu Cristian Scheau Constantin Caruntu Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma Analytical Cellular Pathology |
| title | Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma |
| title_full | Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma |
| title_fullStr | Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma |
| title_full_unstemmed | Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma |
| title_short | Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma |
| title_sort | antitumoral and anti inflammatory roles of somatostatin and its analogs in hepatocellular carcinoma |
| url | http://dx.doi.org/10.1155/2021/1840069 |
| work_keys_str_mv | AT argyriosperiferakis antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma AT georgiostsigas antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma AT aristodemostheodorosperiferakis antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma AT ioanaancabadarau antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma AT andreeaelenascheau antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma AT mirceatampa antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma AT simonaroxanageorgescu antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma AT andreeacristianadidilescu antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma AT cristianscheau antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma AT constantincaruntu antitumoralandantiinflammatoryrolesofsomatostatinanditsanalogsinhepatocellularcarcinoma |